Promising pre-clinical results support advance to clinical study for third combination chemotherapy from Celator based on the company's proprietary
CombiPlex(TM) technology platform.
PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced positive results from preclinical studies to evaluate the optimal ratio of irinotecan and cisplatin to deliver synergistic benefit against a range of tumor cell lines in vitro. The study further worked to develop an effective formulation to maintain the optimal ratio of these drugs in vivo. Results were presented this week in a poster presentation at the AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.
In the study, combinations of irinotecan and cisplatin were applied to a panel of 20 human and murine tumor cell lines enriched with lung tumor carcinomas in vitro to identify the ratios most likely to deliver synergistic benefit. The combination exhibited strong drug ratio dependent synergy. Using Celator's proprietary CombiPlex technology, researchers then engineered a combination of irinotecan and cisplatin in liposomes to maintain a synergistic 7:1 molar ratio following intravenous administration. The product, known as CPX-571, was compared to a combination of irinotecan and cisplatin administered as free drugs, and to monotherapy with each drug agent administered in a liposome formulation in mice implanted with human solid tumor xenografts. In all tumor models tested, CPX-571 showed a high degree of anti-tumor activity and significantly improved efficacy as compared to the combination of free drugs and to the individual liposomal drug agents.
"In this study we were able to identify the optimal ratio of irinotecan
and cisplatin to use in combination chemotherapy and then combine the drugs
in a formulation able to maintain that ratio in animal models. Along with
our progress in developing CPX-1, curre
|SOURCE Celator Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved